Help
Subscribe


GastroHep.com - the global online resource for all aspects of gastroenterology, hepatology and endoscopy

 29 September 2016

Advanced search
GastroHep.com - the global online resource for all aspects of gastroenterology, hepatology and endoscopy Profile of Roy Pounder

Home

News  
Journals
Review Articles
Slide Atlas
Video Clips
Online Books
Advanced Digestive Endoscopy
Classical Cases
Conference Diary
PubMed
International GH Links
USA GH Links
National GH Links
National GI Societies
Other Useful Links




Emails on Gastroenterology and Hepatology
the National AIDS Treatment Advocacy Project
Visit the gastroenterology section of the EUMS

News

New algorithm predicts acute liver failure in drug-induced liver injury

This month's issue of Gastroenterology examines the use of Hy's law and a new composite algorithm to predict acute liver failure in patients with drug-induced liver injury.

News image

Hy's Law, which states that hepatocellular drug-induced liver injury with jaundice indicates a serious reaction, is used widely to determine risk for acute liver failure.

Dr Isabel Lucena and colleagues from Spain optimized the definition of Hy's Law, and developed a model for predicting acute liver failure in patients with drug-induced liver injury.

The researchers collected data from 771 patients with drug-induced liver injury from the Spanish DILI registry, from 1994 through 2012.

The team analyzed data collected at drug-induced liver injury recognition, and at the time of peak levels of alanine aminotransferase (ALT) and total bilirubin.

Of the 771 patients with drug-induced liver injury, 32 developed acute liver failure.

Hepatocellular injury, female sex, high levels of total bilirubin, and a high ratio of aspartate aminotransferase (AST):ALT were independent risk factors for acute liver failure.

An R-based model identified patients who developed acute liver failure with 67% specificity
Gastroenterology

The research team compared 3 ways to use Hy's Law to predict which patients would develop acute liver failure.

All included total bilirubin greater than 2-fold the upper limit of normal (×ULN), and either ALT level greater than 3 × ULN, a ratio (R) value of 5 or greater, or a new ratio (nR) value of 5 or greater.

At recognition of drug-induced liver injury, the R- and nR-based models identified patients who developed acute liver failure with 67% and 63% specificity, respectively, whereas use of only ALT level identified them with 44% specificity.

However, the level of ALT and the nR model each identified patients who developed acute liver failure with 90% sensitivity, whereas the R criteria identified them with 83% sensitivity.

The team found an equal number of patients who did and did not develop ALF had alkaline phosphatase levels greater than 2 × ULN.

The researchers observed that an algorithm based on AST level greater than 17.3 × ULN, total bilirubin greater than 6.6 × ULN, and AST:ALT greater than 1.5 identified patients who developed acute liver failure with 82% specificity and 80% sensitivity.

Dr Lucena's team concludes, "When applied at drug-induced liver injury recognition, the nR criteria for Hy's Law provides the best balance of sensitivity and specificity whereas our new composite algorithm provides additional specificity in predicting the ultimate development of acute liver failure."

Gastroenterol 2014: 147(1): 109–118.e5
03 July 2014

Go to top of page Email this page Email this page to a colleague

 29 September 2016 
Predicting symptomatic outcomes in GERD
 29 September 2016 
Biologic therapies in IBD
 29 September 2016 
Predicting the prognosis of gastric cancer
 28 September 2016 
Global trends in pancreatic cancer mortality
 28 September 2016 
Hep C virus RNA in liver explants
 28 September 2016 
Heterogeneity in endoscopic treatment of Crohn’s
 27 September 2016 
Non-invasive tests of NAFLD
 27 September 2016 
Fecal microbiota transplantation for C.diff in IBD
 27 September 2016 
Fast-track colorectal surgery influences outcomes
 26 September 2016 
Preventing cirrhosis in Hep C with fibrosis
 26 September 2016 
Body image after abdominoperineal excision for rectal cancer
 26 September 2016 
Gastric cancer risk in intestinal metaplasia of the stomach
 23 September 2016 
Sleep quality in nonalcoholic cirrhotic patients
 23 September 2016 
Exercise for NAFLD
 23 September 2016 
BMI history and fatty liver
 22 September 2016 
Predicting small-bowel Crohn’s disease
 22 September 2016 
Colectomy outcomes for ulcerative colitis
 22 September 2016 
Technology vs intervention for weight loss
 21 September 2016 
Employment status and IBD
 21 September 2016 
Cardiopulmonary exercise testing in liver transplant candidates
 21 September 2016 
Patients vs providers on nutrition in IBD
 20 September 2016 
Improving healthcare systems for viral Hepatitis
 20 September 2016 
GI benefits of COX-2 selective inhibitors
 20 September 2016 
Predicting relapse in Crohn's
 19 September 2016 
Prevalence of esophageal cancer in Barrett's
 19 September 2016 
Fecal microbiota transplantation and CDI in IBD
 19 September 2016 
Antibiotic resistance in Helicobacter pylori
 16 September 2016 
Low-residue diet before colonoscopy and bowel cleansing
 16 September 2016 
Genome-wide association in gastric cancer
 16 September 2016 
H. pylori in children with asthma
 15 September 2016 
Improving survival in cholangitis-associated septic shock
 15 September 2016 
Colorectal cancer survival and hospital volumes
 15 September 2016 
Primary sclerosing cholangitis and IBD
 14 September 2016 
Intestinal malabsorption and olmesartan
 14 September 2016 
Infection reduction strategy after colorectal resection
 14 September 2016 
Predicting long-term infliximab use in Crohn's
 13 September 2016 
Predicting survival in refractory celiac disease
 13 September 2016 
Cancer risk stratification in Barrett’s
 13 September 2016 
Screening vs non-screening colonoscopy
 12 September 2016 
Screening in familial colorectal cancer
 12 September 2016 
Metformin improves survival in pancreatic ductal cancer
 12 September 2016 
Consent guidelines for GI endoscopy procedures
 09 September 2016 
Development of IBS
 09 September 2016 
Safe and effective treatment for NASH
 09 September 2016 
Scale for stool measurement in diarrhea-IBS
 08 September 2016 
Prognostic factors for infliximab in Crohn's
 08 September 2016 
Chronic Hep B vs chronic Hep C and mortality
 08 September 2016 
Hematological malignancies in IBD
 07 September 2016 
IBD relapse during pregnancy
 07 September 2016 
New treatments for ulcerative colitis
 07 September 2016 
Alternative to nucleic acid testing in HCV
 06 September 2016 
EHealth technologies in IBD
 06 September 2016 
Endoscopy clinic no-shows
 06 September 2016 
Risk of infection after elective colorectal surgery
 05 September 2016 
Esophageal impedance monitoring
 05 September 2016 
Biomarker for IBD and GI cancer
 05 September 2016 
Family history and IBD clinical course
 02 September 2016 
Dietary carbohydrate intake, insulin resistance and GERD 
 02 September 2016 
Postpolypectomy bleeding in the colorectum
 02 September 2016 
Postop recurrence of Crohn's

Blackwell Publishing


GastroHep.com is a Blackwell Publishing registered trademark
© 2016 Wiley-Blackwell and GastroHep.com and contributors
Privacy Statement
Disclaimer
About Us